Peptide science, clearly referenced.
Independent, literature-backed explainers on research compounds — every claim cited to PubMed, every framing strictly research-use-only.
Is NMN legal in Europe? It is classified as a Novel Food — and as of 2026 still unauthorised, with EFSA opinions in and applications pending. The honest, source-cited answer for researchers.
NAD+ degrades faster than most researchers expect. This guide covers the real chemistry — hydrolysis, pH sensitivity, thermal lability — and the exact conditions a lab should maintain for a lyophilised NAD+ reference material.
How to store 5-Amino-1MQ (5-amino-1-methylquinolinium) correctly: solid vs DMSO solution stability, temperature, humidity, freeze-thaw cycles, and reconstitution guidance for research use only.
An honest comparison of how methylene blue behaves in solid capsule form vs aqueous solution — covering photosensitivity, azure B impurities, stability windows, and what each format means for a research workflow.
Why NMN is among the most handling-sensitive nucleotide reference materials: hygroscopicity, thermal stability, solid vs solution, and verified laboratory practices for keeping the compound intact.
How a BPC-157 COA actually verifies the molecule: HPLC area-% purity, mass-spectrometry identity against the 15-amino-acid sequence, and the SPPS impurities to look for.
A mechanism-level research guide to Semax, the ACTH(4-10)-Pro-Gly-Pro heptapeptide: BDNF/NGF transcription, the dopaminergic system, and an honest read of animal-heavy and limited clinical evidence. Research use only.
A mechanism-level research guide to Selank, the tuftsin analogue Thr-Lys-Pro-Arg-Pro-Gly-Pro: enkephalinase inhibition, GABAergic and serotonergic signalling, gene-expression effects, and an honest read of animal-heavy evidence. Research use only.
A research-use guide to ipamorelin: how it engages the ghrelin receptor (GHS-R1a), why it is described as the first selective GH secretagogue, and an honest read of the animal and limited human data. RUO reference only.
KPV and larazotide are both studied in intestinal-barrier and inflammation research, but by different mechanisms. A sober, RUO comparison — including larazotide's negative phase III result. References verified.